LEVATOL
LOE Approachingpenbutolol sulfate
NDAORALTABLET
Approved
Dec 1987
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 13h ago · AI intelligence enriched 2mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LEVATOL (penbutolol sulfate) is an oral beta-adrenergic blocking agent approved in 1987 for the treatment of hypertension. It functions as a selective beta-1 blocker with intrinsic sympathomimetic activity, reducing blood pressure through decreased cardiac output and peripheral vascular resistance. The drug is indicated for patients requiring antihypertensive therapy.
LOE Approaching
LEVATOL faces intensifying generic competition with moderate competitive pressure (30/100), limiting growth opportunities and reducing brand team headcount.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
LEVATOL offers limited career growth due to its LOE-approaching lifecycle and minimal linked job openings. Roles are primarily defensive, focused on protecting market share and managing generic competition rather than driving innovation or expansion.
Brand ManagerField Sales Representative
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.